The Harrington Discovery Institute, part of The Harrington Project for Discovery & Development based in Cleveland, Ohio, supports the efforts of physician-scientists to advance drug therapies that will improve lives of patients. In a similar mission, the Alzheimer’s Drug Discovery Foundation (ADDF) provides funding to accelerate scientists’ efforts to develop drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.
The ADDF follows a venture philanthropy model, funding research in academia and the biotechnology industry. And it’s the only such charity solely dedicated to funding the development of drugs for Alzheimer’s disease. Through the support of its donors, the ADDF has awarded more than $70 million to fund over 450 Alzheimer’s drug discovery programs and clinical trials in 18 countries.
In 2013 the Alzheimer’s Drug Discovery Foundation and the Harrington Discovery Institute formed a mission aligned partnership to leverage their combined expertise and resources to advance highly promising Alzheimer’s disease discovery projects conducted in academic medical institutions nationwide and established the ADDF-Harrington Scholar Program.
ADDF-Harrington Scholars get funding from ADDF and strategic advising and mentoring from experts in pharmaceutical development through the Harrington Discovery Institute’s Innovation Support Center to chart a path from the bench to the clinic. ADDF-Harrington Scholars also have facilitated access to BioMotiv, a for-profit bio-accelerator associated with The Harrington Project and aligned with the Harrington Discovery Institute in mission and structure.
Learn more about the scholars and their research.
Award Program Details.
Harrington InnovationSupport Center